Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Benzylimidazole. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 known ✓ | P11511 | 6/20 | 0.96 |
| ▸ | CYP11B1 | P15538 | 16/20 | 0.96 |
| ▸ | CYP11B2 | P19099 | 13/20 | 0.96 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.96 |
| ▸ | POLB | P06746 | 1/20 | 0.96 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.96 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.96 |
| ▸ | MAPT | P10636 | 1/20 | 0.96 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.96 |
| ▸ | QPCT | Q16769 | 1/20 | 0.96 |
| ▸ | CYP4Z1 | Q86W10 | 1/20 | 0.96 |
| ▸ | QPCTL | Q9NXS2 | 1/20 | 0.96 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.77 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.67 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Benzylimidazole SCHEMBL414 | 0.98 | CYP11B1 (1.00) | CYP11B1CYP11B2CYP19A1CYP1A2POLB | |
| SCHEMBL22063900 | 0.98 | CYP11B1 (1.00) | CYP11B1CYP11B2CYP19A1CYP1A2POLB | |
| Benzylimidazole SCHEMBL3786782 | 0.96 | CYP11B1 (0.96) | CYP11B1CYP11B2CYP19A1CYP1A2POLB | |
| Benzylimidazole SCHEMBL29239318 | 0.96 | CYP11B1 (0.96) | CYP11B1CYP11B2CYP19A1CYP1A2POLB | |
| Benzylimidazole SCHEMBL31453527 | 0.96 | CYP11B1 (0.96) | CYP11B1CYP11B2CYP19A1CYP1A2POLB | |
| Benzylimidazole SCHEMBL16237308 | 0.96 | CYP11B1 (0.96) | CYP11B1CYP11B2CYP19A1CYP1A2POLB | |
| Benzylimidazole SCHEMBL27803894 | 0.92 | CYP11B1 (0.89) | CYP11B1CYP11B2CYP19A1CYP1A2POLB | |
| Benzylimidazole SCHEMBL28764644 | 0.91 | CYP11B1 (0.86) | CYP11B1CYP11B2CYP19A1CYP1A2POLB | |
| Benzylimidazole SCHEMBL27535101 | 0.91 | CYP11B1 (0.86) | CYP11B1CYP11B2CYP19A1CYP1A2POLB | |
| Benzylimidazole SCHEMBL7942345 | 0.90 | CYP11B1 (0.77) | CYP11B1CYP11B2CYP19A1CYP1A2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109957286-A | Ink and its preparation method and application | 深圳市百柔新材料技术有限公司 | 2019-07-02 | — | — | CN | claimed |
| CN-108136366-A | molecularly imprinted polymer | 相位全息成像PHI有限公司 | 2018-06-08 | — | — | CN | claimed |
| US-20120020915-A1 | Compounds and Methods for Treating Cancer and Diseases of the Central Nervous System | QUEENS UNIVERSITY AT KINGSTON (CA) | 2012-01-26 | — | — | US | claimed |
| US-20110319459-A1 | Compounds and Methods for Treating Cancer and Diseases of the Central Nervous System | OSTA BIOTECHNOLOGIES (CA) | 2011-12-29 | — | — | US | claimed |
| EP-2173740-A1 | HEME-OXYGENASE INHIBITORS AND USE OF THE SAME IN THE TREATMENT OF CANCER AND DISEASES OF THE CENTRAL NERVOUS SYSTEM | Osta Biotechnologies (CA) | 2010-04-14 | — | — | EP | claimed |
| US-20090176831-A1 | Compounds and Methods for Treating Cancer and Diseases of the Central Nervous System | OSTA BIOTECHNOLOGIES (CA) | 2009-07-09 | — | — | US | claimed |
| WO-2008151437-A1 | HEME-OXYGENASE INHIBITORS AND USE OF THE SAME IN THE TREATMENT OF CANCER AND DISEASES OF THE CENTRAL NERVOUS SYSTEM | OSTA BIOTECHNOLOGIES (CA) | 2008-12-18 | — | — | WO | claimed |
| EP-1094706-A1 | PROCESS FOR THE BIOCIDAL TREATMENT OF SURFACES | RHODIA CHIMIE (FR) | 2001-05-02 | — | — | EP | claimed |
| WO-2000002449-A1 | PROCESS FOR THE BIOCIDAL TREATMENT OF SURFACES | RHODIA CHIMIE (FR) | 2000-01-20 | — | — | WO | claimed |
| US-20250270537-A1 | METHODS FOR NUCLEIC ACID CAPTURE | ZYMO RESEARCH CORPORATION (US) | 2025-08-28 | — | — | US | disclosed |
| US-20220186207-A1 | METHODS FOR NUCLEIC ACID CAPTURE | ZYMO RES CORPORATION (US) | 2022-06-16 | — | — | US | disclosed |
| US-11236325-B2 | Methods for nucleic acid capture | ZYMO RESEARCH CORPORATION (US) | 2022-02-01 | — | — | US | disclosed |
| US-11214715-B2 | Ionic polymers and their use as wet-adhesives and coatings | ACatechol, Inc. (US) | 2022-01-04 | — | — | US | disclosed |
| CN-107427869-B | Heavy metal fixing agent for treating ash and method for treating ash using same | 栗田工业株式会社 | 2021-02-02 | — | — | CN | disclosed |
| EP-1324821-A2 | EMULSION COMPRISING A BLEND OF CATIONIC, ANIONIC AND BRIDGING SURFACTANS, OIL AND WATER | STEPAN COMPANY (US) | 2003-07-09 | — | — | EP | disclosed |
| EP-1320354-A2 | SHAMPOO AND BODY WASH COMPOSITION | STEPAN COMPANY (US) | 2003-06-25 | — | — | EP | disclosed |
| WO-2002022083-A2 | EMULSION COMPRISING A BLEND OF CATIONIC, ANIONIC AND BRIDGING SURFACTANTS, OIL AND WATER | STEPAN COMPANY (US) | 2002-03-21 | — | — | WO | disclosed |
| WO-2002022105-A2 | SHAMPOO AND BODY WASH COMPOSITION | STEPAN COMPANY (US) | 2002-03-21 | — | — | WO | disclosed |
| EP-0056664-B1 | ADDITION POLYMERS AND METAL COMPLEXES THEREOF | EASTMAN KODAK COMPANY (a New Jersey corporation) (US) | 1986-11-12 | — | — | EP | disclosed |
| US-4032596-A | QUATERNARY AMMONIUM SALTS, FREE RADICAL CATALYSTS | AIR PRODUCTS AND CHEMICALS, INC. (US) | 1977-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110319459-A1 | Compounds and Methods for Treating Cancer and Diseases of the Central Nervous System | TXNRD2, HMOX1, HMOX2 | CYP19A1 884/4885CYP11B1 61/4885CYP11B2 68/4885 |
| US-20120020915-A1 | Compounds and Methods for Treating Cancer and Diseases of the Central Nervous System | HMOX1, HMOX2, CYC1 | CYP19A1 641/4885CYP11B1 63/4885CYP11B2 60/4885 |
| US-20090176831-A1 | Compounds and Methods for Treating Cancer and Diseases of the Central Nervous System | HMOX1, HMOX2, CYC1 | CYP19A1 614/4885CYP11B1 55/4885CYP11B2 52/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.